Immunoregulation / Cell-Directed Therapy
Gruppe von Gunten

Unser Labor erforscht molekulare Mechanismen und Medikamente, die Entzündungen und Krebs beeinflussen. Insbesondere konzentrieren wir uns auf Protein-Kohlenhydrat-Interaktionen im Immunsystem und auf entzündungshemmende Effekte, die durch Siglec-Rezeptoren vermittelt werden. Siglecs sind Kohlenhydrat-bindende Rezeptoren (Lektine), die in letzter Zeit aufgrund ihrer Fähigkeit, Zelltod, antiproliferative Effekte und die Hemmung zellulärer Aktivitäten zu vermitteln, besondere Aufmerksamkeit erfahren haben. Wir haben kürzlich natürliche Autoantikörper im humanen intravenösen Immunglobulin (IVIG) als endogene Siglec-Rezeptor-Liganden identifiziert. 

Der Gruppenleiter Prof. Dr. S. von Gunten ist Mitglied des Consortium of Functional Glycomics (www.functionalglycomics.org), das von den US National Institutes of Health (NIH) gefördert wird und Paradigmen definiert, durch die Protein-Kohlenhydrat-Interaktionen die Zellkommunikation vermitteln. Unsere Gruppe kooperiert mit WissenschaftlerInnen und KlinikerInnen zahlreicher internationaler und lokaler akademischer Einrichtungen, Unternehmen und Spitäler.

Project leader: Prof. Stephan von Gunten

Image: S1P in fibrotic niche

Glycolipids and sphingosine-1-phosphate (S1P) in kidney health and disease

This project investigates how naturally occurring fats and sugar-linked fats in the body—known as lipids and glycolipids—help maintain kidney health and contribute to disease. A central focus is a molecule called sphingosine-1-phosphate (S1P), which acts as a key messenger between cells, guiding how they respond to stress and injury. Although S1P is known to be important, its precise role within certain kidney cells remains unclear. The research centers on podocytes, highly specialized cells that form a crucial part of the kidney’s filtration system. These cells prevent essential proteins from leaking into the urine. When podocytes are damaged, this protective barrier breaks down, leading to conditions marked by protein loss (albuminuria), inflammation, and scarring (fibrosis). Our work examines how changes in S1P levels inside cells influence podocyte behavior and their communication with neighboring cells. We pay particular attention to the enzymes that regulate S1P, as they may play a decisive role in how kidney diseases develop and how patients respond to treatment. In addition, we study glycosphingolipids—molecules formed when sugars attach to lipids—which are involved in “outside-in” signaling and interactions between podocytes and immune cells. These processes are essential for preserving the integrity of the kidney’s filtration barrier. A key aim of the project is to understand why some patients do not respond well to standard steroid therapies and to identify more effective alternatives. By uncovering these underlying mechanisms, this research seeks to open new paths for treatment and ultimately improve outcomes for people living with kidney disease.

Prof. Dr. Stephan von Gunten, MD, PhD, MME​

Gruppenmitglieder

ehemalige Gruppenmitglieder

Alisha Eigenheer (2026)
Dr. Aref Hosseini, (2020-2026)
Barbara Márquez Gutiérrez, (2026)
Elena Sita Schranz (2026)
Sheila Romina Pasi (2026)
Mathangi Sivaseelan (2024-2025)
Jennice Pick, Masterstudentin (2024-2025)
Riim Nasser, Laborantin (2018-2025)
Dr. Quentin Haas
Dr. Kayluz Frias Boligan
Dr. Stefanie Graeter
Dr. Fabiola Schorer
Dr. Christoph Schneider
Dr. Thomas Demoulins, Postdoc (2010-2012)
Dr. Dr. Camilla Jandus, Postdoc (2010-2012)
Dr. Dr. Marc Wehrli, MD Doktorand (2010-2013)  

Publication Year Type